Imaging of gastrinomas by nuclear medicine methods.
Identifieur interne : 002693 ( Main/Exploration ); précédent : 002692; suivant : 002694Imaging of gastrinomas by nuclear medicine methods.
Auteurs : RBID : pubmed:17985094English descriptors
- KwdEn :
- Disease Progression, Duodenal Neoplasms (blood), Duodenal Neoplasms (pathology), Duodenal Neoplasms (radionuclide imaging), Gastrinoma (blood), Gastrinoma (pathology), Gastrinoma (radionuclide imaging), Gastrins (blood), Humans, Indium Radioisotopes (diagnostic use), Multiple Endocrine Neoplasia Type 1 (blood), Multiple Endocrine Neoplasia Type 1 (pathology), Multiple Endocrine Neoplasia Type 1 (radionuclide imaging), Neoplasm Staging, Octreotide (diagnostic use), Pancreatic Neoplasms (blood), Pancreatic Neoplasms (pathology), Pancreatic Neoplasms (radionuclide imaging), Receptors, Somatostatin (analysis), Sensitivity and Specificity.
- MESH :
- chemical , analysis : Receptors, Somatostatin.
- chemical , blood : Gastrins.
- blood : Duodenal Neoplasms, Gastrinoma, Multiple Endocrine Neoplasia Type 1, Pancreatic Neoplasms.
- chemical , diagnostic use : Indium Radioisotopes, Octreotide.
- pathology : Duodenal Neoplasms, Gastrinoma, Multiple Endocrine Neoplasia Type 1, Pancreatic Neoplasms.
- radionuclide imaging : Duodenal Neoplasms, Gastrinoma, Multiple Endocrine Neoplasia Type 1, Pancreatic Neoplasms.
- Disease Progression, Humans, Neoplasm Staging, Sensitivity and Specificity.
Abstract
Somatostatin receptor scintigraphy (SRS) is a valuable method for the detection of somatostatin receptor-positive lesions. Most gastrinomas (over-)express the somatostatin receptor subtype 2 which can be targeted by In-111 labeled Octreotide. Different studies show a high sensitivity of SRS for the localization and staging of gastrinomas. SRS seems to be superior to other non-invasive imaging modalities and has been proven to significantly contribute to patient management. However, the sensitivity depends on the size and exact localization of the tumors. Smaller lesions and lesions located in the duodenum show a significantly lower sensitivity. In any case, SRS belongs to the routine imaging procedure for gastrinomas for localization and staging and can also be used for evaluation of the tumor progression.
DOI: 10.1007/s00508-007-0881-5
PubMed: 17985094
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Imaging of gastrinomas by nuclear medicine methods.</title><author><name sortKey="Behe, Martin" uniqKey="Behe M">Martin Béhé</name><affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, Philipps-University of Marburg, Marburg, Germany. behe@staff.uni-marburg.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Nuclear Medicine, Philipps-University of Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Gotthardt, Martin" uniqKey="Gotthardt M">Martin Gotthardt</name></author><author><name sortKey="Behr, Thomas M" uniqKey="Behr T">Thomas M Behr</name></author></titleStmt><publicationStmt><date when="2007">2007</date><idno type="doi">10.1007/s00508-007-0881-5</idno><idno type="RBID">pubmed:17985094</idno><idno type="pmid">17985094</idno><idno type="wicri:Area/Main/Corpus">002602</idno><idno type="wicri:Area/Main/Curation">002602</idno><idno type="wicri:Area/Main/Exploration">002693</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disease Progression</term><term>Duodenal Neoplasms (blood)</term><term>Duodenal Neoplasms (pathology)</term><term>Duodenal Neoplasms (radionuclide imaging)</term><term>Gastrinoma (blood)</term><term>Gastrinoma (pathology)</term><term>Gastrinoma (radionuclide imaging)</term><term>Gastrins (blood)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Multiple Endocrine Neoplasia Type 1 (blood)</term><term>Multiple Endocrine Neoplasia Type 1 (pathology)</term><term>Multiple Endocrine Neoplasia Type 1 (radionuclide imaging)</term><term>Neoplasm Staging</term><term>Octreotide (diagnostic use)</term><term>Pancreatic Neoplasms (blood)</term><term>Pancreatic Neoplasms (pathology)</term><term>Pancreatic Neoplasms (radionuclide imaging)</term><term>Receptors, Somatostatin (analysis)</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Gastrins</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Duodenal Neoplasms</term><term>Gastrinoma</term><term>Multiple Endocrine Neoplasia Type 1</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Duodenal Neoplasms</term><term>Gastrinoma</term><term>Multiple Endocrine Neoplasia Type 1</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Duodenal Neoplasms</term><term>Gastrinoma</term><term>Multiple Endocrine Neoplasia Type 1</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Neoplasm Staging</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Somatostatin receptor scintigraphy (SRS) is a valuable method for the detection of somatostatin receptor-positive lesions. Most gastrinomas (over-)express the somatostatin receptor subtype 2 which can be targeted by In-111 labeled Octreotide. Different studies show a high sensitivity of SRS for the localization and staging of gastrinomas. SRS seems to be superior to other non-invasive imaging modalities and has been proven to significantly contribute to patient management. However, the sensitivity depends on the size and exact localization of the tumors. Smaller lesions and lesions located in the duodenum show a significantly lower sensitivity. In any case, SRS belongs to the routine imaging procedure for gastrinomas for localization and staging and can also be used for evaluation of the tumor progression.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17985094</PMID><DateCreated><Year>2007</Year><Month>11</Month><Day>06</Day></DateCreated><DateCompleted><Year>2008</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0043-5325</ISSN><JournalIssue CitedMedium="Print"><Volume>119</Volume><Issue>19-20</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Wiener klinische Wochenschrift</Title><ISOAbbreviation>Wien. Klin. Wochenschr.</ISOAbbreviation></Journal><ArticleTitle>Imaging of gastrinomas by nuclear medicine methods.</ArticleTitle><Pagination><MedlinePgn>593-6</MedlinePgn></Pagination><Abstract><AbstractText>Somatostatin receptor scintigraphy (SRS) is a valuable method for the detection of somatostatin receptor-positive lesions. Most gastrinomas (over-)express the somatostatin receptor subtype 2 which can be targeted by In-111 labeled Octreotide. Different studies show a high sensitivity of SRS for the localization and staging of gastrinomas. SRS seems to be superior to other non-invasive imaging modalities and has been proven to significantly contribute to patient management. However, the sensitivity depends on the size and exact localization of the tumors. Smaller lesions and lesions located in the duodenum show a significantly lower sensitivity. In any case, SRS belongs to the routine imaging procedure for gastrinomas for localization and staging and can also be used for evaluation of the tumor progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Béhé</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Affiliation>Department of Nuclear Medicine, Philipps-University of Marburg, Marburg, Germany. behe@staff.uni-marburg.de</Affiliation></Author><Author ValidYN="Y"><LastName>Gotthardt</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Behr</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Klin Wochenschr</MedlineTA><NlmUniqueID>21620870R</NlmUniqueID><ISSNLinking>0043-5325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Gastrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>somatostatin receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Duodenal Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Gastrinoma</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Gastrins</DescriptorName><QualifierName MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Multiple Endocrine Neoplasia Type 1</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-007-0881-5</ArticleId><ArticleId IdType="pubmed">17985094</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002693 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002693 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17985094
|texte= Imaging of gastrinomas by nuclear medicine methods.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17985094" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |